Phillip Gu1, Anshika Kapur2, Dalin Li2, Talin Haritunians2, Eric Vasiliauskas2, David Q Shih2, Stephan R Targan2, Brennan Mr Spiegel3, Dermot Pb Mcgovern2, Jeanne T Black4, Gil Y Melmed2. 1. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. 2. F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 3. Department of Health Services Research, Center for Outcomes Research and Education, Cedars-Sinai Health System, Los Angeles, California, USA. 4. Department of Resource & Outcomes Management, Cedars-Sinai Health System, Los Angeles, California, USA.
Abstract
OBJECTIVE: Inflammatory bowel diseases (IBD) are associated with significant morbidity and economic burden. The variable course of IBD creates a need for predictors of clinical outcomes and health resource utilization (HRU) to guide treatment decisions. We aimed to identify clinical, serological or genetic markers associated with inpatient resource utilization in patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Patients with IBD with available genetic and serological data who had at least one emergency department visit or hospitalization in a 3-year period were included. The primary outcome measure was HRU, as measured by the All Patient Refined Diagnosis Related Group classification system. Univariate and multivariate linear and logistic regression models were used to identify the associations with HRU. RESULTS: Altogether 858 (562 CD and 296 UC) patients were included. Anti-CBir1 seropositivity (P = 0.002, effect size [ES]: 0.762, 95% confidence interval [CI] 0.512-1.012) and low socioeconomic status (P = 0.005, ES: 1.620 [95% CI 1.091-2.149]) were independently associated with a high HRU. CD diagnosis (P = 0.006, ES: -0.701 [95% CI -0.959 to -0.443]) was independently associated with a low inpatient HRU. CONCLUSION: In patients with IBD who required at least one emergency department visit or hospitalization, anti-CBir1 antibody status may be a useful biomarker of HRU when formulating management strategies to reduce disease complications and resource utilization.
OBJECTIVE:Inflammatory bowel diseases (IBD) are associated with significant morbidity and economic burden. The variable course of IBD creates a need for predictors of clinical outcomes and health resource utilization (HRU) to guide treatment decisions. We aimed to identify clinical, serological or genetic markers associated with inpatient resource utilization in patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS:Patients with IBD with available genetic and serological data who had at least one emergency department visit or hospitalization in a 3-year period were included. The primary outcome measure was HRU, as measured by the All Patient Refined Diagnosis Related Group classification system. Univariate and multivariate linear and logistic regression models were used to identify the associations with HRU. RESULTS: Altogether 858 (562 CD and 296 UC) patients were included. Anti-CBir1 seropositivity (P = 0.002, effect size [ES]: 0.762, 95% confidence interval [CI] 0.512-1.012) and low socioeconomic status (P = 0.005, ES: 1.620 [95% CI 1.091-2.149]) were independently associated with a high HRU. CD diagnosis (P = 0.006, ES: -0.701 [95% CI -0.959 to -0.443]) was independently associated with a low inpatient HRU. CONCLUSION: In patients with IBD who required at least one emergency department visit or hospitalization, anti-CBir1 antibody status may be a useful biomarker of HRU when formulating management strategies to reduce disease complications and resource utilization.
Authors: Andrea D Tyler; Raquel Milgrom; Wei Xu; Joanne M Stempak; A Hillary Steinhart; Robin S McLeod; Gordon R Greenberg; Zane Cohen; Mark S Silverberg Journal: Clin Gastroenterol Hepatol Date: 2011-10-01 Impact factor: 11.382
Authors: Orlaith B Kelly; Morgan Rosenberg; Andrea D Tyler; Joanne M Stempak; A Hillary Steinhart; Zane Cohen; Gordon R Greenberg; Mark S Silverberg Journal: J Crohns Colitis Date: 2015-12-30 Impact factor: 9.071
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Lok Wong Samson; Kenneth Finegold; Azeem Ahmed; Matthew Jensen; Clara E Filice; Karen E Joynt Journal: Med Care Date: 2017-12 Impact factor: 2.983
Authors: Michael J Lodes; Yingzi Cong; Charles O Elson; Raodoh Mohamath; Carol J Landers; Stephan R Targan; Madeline Fort; Robert M Hershberg Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Mirthe Emilie van der Valk; Marie-Josée J Mangen; Max Leenders; Gerard Dijkstra; Ad A van Bodegraven; Herma H Fidder; Dirk J de Jong; Marieke Pierik; C Janneke van der Woude; Mariëlle J L Romberg-Camps; Cees H M Clemens; Jeroen M Jansen; Nofel Mahmmod; Paul C van de Meeberg; Andrea E van der Meulen-de Jong; Cyriel Y Ponsioen; Clemens J M Bolwerk; J Reinoud Vermeijden; Peter D Siersema; Martijn G H van Oijen; Bas Oldenburg Journal: Gut Date: 2012-11-07 Impact factor: 23.059
Authors: Phillip Gu; Eric Clifford; Andrew Gilman; Christopher Chang; Elizabeth Moss; David I Fudman; Phillip Kilgore; Urska Cvek; Marjan Trutschl; J Steven Alexander; Ezra Burstein; Moheb Boktor Journal: Pathophysiology Date: 2022-07-18